Why is Natera stock sliding today?

Natera's stock plummeted nearly 6.0% in afternoon trading after a swift reversal, soaring to a 52-week high of $437.41 before collapsing to $400.31. This downward trend, reminiscent of profit-taking following a technical peak, persisted despite a cascade of positive company-specific news. Citi raised its price target to $480 from $365, maintaining a Buy rating.

Natera unveiled new Signatera data at the American Society for Radiation Oncology’s 2026 Annual Meeting, marking its inaugural participation at the ASTRO conference. Moreover, the AFT-70 NAVIGATE Phase III breast cancer trial, co-funded with Genentech and utilizing Natera's Signatera platform, was formally announced. The stock's performance, however, remained out of sync with the broader market, as both the S&P 500 and Nasdaq continued to climb.

Recently disclosed SEC filings revealed insider selling by the CEO and the clinical diagnostics president, indicating a cautious sentiment. Despite the lack of macro headwinds or adverse central bank announcements, Natera's stock drop highlighted a classic scenario of 'buy the news, sell the fact': a stock that had surged significantly on strong catalysts eventually fell victim to aggressive profit-taking, driven by investors concerned about a valuation that far exceeded consensus targets and fundamental fair-value estimates.